Literature DB >> 34193961

Treatment of mixed depression with theta-burst stimulation (TBS): results from a double-blind, randomized, sham-controlled clinical trial.

Diego Freitas Tavares1,2, Paulo Suen3, Carla Garcia Rodrigues Dos Santos2, Doris Hupfeld Moreno2, Leandro Da Costa Lane Valiengo1, Izio Klein1, Lucas Borrione1, Pamela Marques Forte2, André R Brunoni4,5, Ricardo Alberto Moreno2.   

Abstract

Mixed depression is probably different in terms of clinical course and response to treatment. Repetitive transcranial magnetic stimulation (rTMS) is well established in non-mixed depression, and theta-burst stimulation (TBS) protocol is replacing conventional protocols because of noninferiority and reduced delivery time. However, TBS has not been adequately studied in mixed states. This study was a double-blind, six-week, sham-controlled, and randomized clinical trial of bilateral TBS targeting the right and left dorsolateral prefrontal cortex, respectively. Adults with bipolar and major depressive disorder experiencing an acute mixed depression were eligible if they had not benefited from a first- or second-line treatment for acute unipolar or bipolar depression recommended by the Canadian Network for Mood and Anxiety Treatments. Out of 100 patients included, 90 composed modified intention-to-treat sample, which was patients that completed at least one week of the intervention. There were no significant differences in Montgomery-Asberg depression rating scale score changes (least squares mean difference between groups at week 3, -0.06 [95% CI, - 3.39 to 3.51; P = 0.97] in favor of sham TBS). Response and remission rates per MADRS were also not statistically different among active and sham groups (35.7% vs. 43.7%, and 28.5% vs. 37.5% respectively at week 6, ps > 0.51). No other analyses from baseline to weeks 3 or 6 revealed significant time x group interaction or mean differences among groups in the mITT sample. Bilateral TBS targeting the DLPFC is not efficacious as an add-on treatment of acute bipolar and unipolar mixed depression. ClinicalTrials.govIdentifier: NCT04123301.

Entities:  

Year:  2021        PMID: 34193961     DOI: 10.1038/s41386-021-01080-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  80 in total

1.  Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity.

Authors:  Petra Zimmermann; Tanja Brückl; Agnes Nocon; Hildegard Pfister; Roselind Lieb; Hans-Ulrich Wittchen; Florian Holsboer; Jules Angst
Journal:  Arch Gen Psychiatry       Date:  2009-12

2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 3.  Delayed sleep phase syndrome and bipolar disorder: Pathogenesis and available common biomarkers.

Authors:  Farid Talih; Nour Y Gebara; Farah S Andary; Stefania Mondello; Firas Kobeissy; Raffaele Ferri
Journal:  Sleep Med Rev       Date:  2018-02-13       Impact factor: 11.609

4.  DSM-5-defined 'mixed features' and Benazzi's mixed depression: which is practically useful to discriminate bipolar disorder from unipolar depression in patients with depression?

Authors:  Minoru Takeshima; Takashi Oka
Journal:  Psychiatry Clin Neurosci       Date:  2014-07-14       Impact factor: 5.188

5.  The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project.

Authors:  Roger S McIntyre; Joanna K Soczynska; Danielle S Cha; Hanna O Woldeyohannes; Roman S Dale; Mohammad T Alsuwaidan; Laura Ashley Gallaugher; Rodrigo B Mansur; David J Muzina; Andre Carvalho; Sidney H Kennedy
Journal:  J Affect Disord       Date:  2014-10-12       Impact factor: 4.839

6.  The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013.

Authors:  Alize J Ferrari; Emily Stockings; Jon-Paul Khoo; Holly E Erskine; Louisa Degenhardt; Theo Vos; Harvey A Whiteford
Journal:  Bipolar Disord       Date:  2016-08       Impact factor: 6.744

7.  DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.

Authors:  R S McIntyre; M Tohen; M Berk; J Zhao; E Weiller
Journal:  J Affect Disord       Date:  2013-05-25       Impact factor: 4.839

8.  Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study.

Authors:  Dina Popovic; Eduard Vieta; Jean-Michel Azorin; Jules Angst; Charles L Bowden; Sergey Mosolov; Allan H Young; Giulio Perugi
Journal:  Bipolar Disord       Date:  2015-09-29       Impact factor: 6.744

9.  Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD.

Authors:  Joseph F Goldberg; Roy H Perlis; Charles L Bowden; Michael E Thase; David J Miklowitz; Lauren B Marangell; Joseph R Calabrese; Andrew A Nierenberg; Gary S Sachs
Journal:  Am J Psychiatry       Date:  2009-01-02       Impact factor: 18.112

10.  Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010.

Authors:  Alize J Ferrari; Fiona J Charlson; Rosana E Norman; Scott B Patten; Greg Freedman; Christopher J L Murray; Theo Vos; Harvey A Whiteford
Journal:  PLoS Med       Date:  2013-11-05       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.